Aurinia Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUPH research report →
Companywww.auriniapharma.com
Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- CEO
- Kevin C. Tang
- IPO
- 2014
- Employees
- 130
- HQ
- Edmonton, BC, CA
Price Chart
Valuation
- Market Cap
- $2.04B
- P/E
- 7.06
- P/S
- 6.85
- P/B
- 3.71
- EV/EBITDA
- 12.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.74%
- Op Margin
- 41.73%
- Net Margin
- 99.97%
- ROE
- 64.48%
- ROIC
- 18.99%
Growth & Income
- Revenue
- $283.06M · 20.38%
- Net Income
- $287.20M · 4893.08%
- EPS
- $2.14 · 5250.00%
- Op Income
- $104.91M
- FCF YoY
- 206.99%
Performance & Tape
- 52W High
- $16.88
- 52W Low
- $7.29
- 50D MA
- $15.35
- 200D MA
- $14.18
- Beta
- 1.45
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on AUPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Robertson Stephen P. | other | 115,541 |
| May 18, 26 | Hearne Michael S | other | 116,144 |
| May 18, 26 | Hearne Michael S | other | 70,230 |
| May 18, 26 | Cole Ryan | other | 116,144 |
| May 18, 26 | Cole Ryan | other | 70,230 |
| Mar 23, 26 | Cole Ryan | other | 0 |
| Mar 23, 26 | Hearne Michael S | other | 0 |
| Mar 6, 26 | Keenan Greg | other | 8,069 |
| Mar 3, 26 | TANG KEVIN | buy | 184,208 |
| Mar 2, 26 | TANG KEVIN | buy | 115,792 |
Our AUPH Coverage
We haven't published any research on AUPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AUPH Report →